BLA 761408 · Eli Lilly and CO
Onswik
Insulin Efsitora Alfa-Gobe · Subcutaneous
NovelCDER novel approval, Sep 23, 2026: To improve glycemic control in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise
Last checked: Nov 20, 2026Latest source record: Sep 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Sep 23, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
5
5 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 23, 2026.
ONSWIK™ is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ONSWIK™ is a long-acting insulin analog indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: Not recommended for use in patients with type 1 diabetes mellitus due to increased risk of severe hypoglycemia ( 1 ) Limitations of Use ONSWIK is not recommended for use in patients with type 1 diabetes mellitus due to increased risk of severe hypoglycemia. [see Warnings and Precautions ( 5.2 )] .
Mechanism: The primary activity of ONSWIK is the regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin also inhibits lipolysis and proteolysis and enhances protein synthesis. The protracted time-action profile of ONSWIK results from reduced renal clearance due to its relatively large molecular size, inhibition of degradation due to binding at the neonatal Fc receptor, and reduced affinity relative to human insulin for the insulin receptor, which...
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- ONSWIK · INSULIN EFSITORA ALFA-GOBE 1000 UNITS/ML · INJECTABLE, SUBCUTANEOUS · Prescription
- ONSWIK · INSULIN EFSITORA ALFA-GOBE 500 UNITS/ML · INJECTABLE, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Insulin Efsitora Alfa" as an intervention, any sponsor and status, largest first.
- A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal InsulinPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT05275400 · 986 participants · Start Mar 8, 2022 · Primary completion May 15, 2024
Drug: Insulin Efsitora Alfa; Insulin Degludec · For: Type 2 Diabetes
Sites: Little Rock, Arkansas; Concord, California; Escondido, California · 127 sites in all
- A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First TimePivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT05362058 · 928 participants · Start Jun 3, 2022 · Primary completion Apr 10, 2024
Drug: Insulin Efsitora Alfa; Insulin Degludec · For: Diabetes; Type 2 Diabetes
Sites: Escondido, California; Fresno, California; Greenbrae, California · 113 sites in all
- A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)Pivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT05662332 · 795 participants · Start Jan 14, 2023 · Primary completion Jul 19, 2024
Drug: Insulin Efsitora Alfa; Insulin Glargine · For: Type 2 Diabetes; T2D
Sites: Birmingham, Alabama; Sheffield, Alabama; Escondido, California · 71 sites in all
- A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily InjectionsPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT05462756 · 730 participants · Start Aug 11, 2022 · Primary completion Feb 27, 2024
Drug: Insulin Efsitora Alfa; Insulin Lispro (U100) and 1 more · For: Type 2 Diabetes; Type 2 Diabetes Treated With Insulin
Sites: Hamden, Connecticut; Clearwater, Florida; Miami Lakes, Florida · 81 sites in all
- A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection TherapyPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT05463744 · 692 participants · Start Aug 12, 2022 · Primary completion May 7, 2024
Drug: Insulin Efsitora Alfa; Insulin Degludec · For: Type 1 Diabetes; Diabetes
Sites: Concord, California; Fresno, California; Montclair, California · 83 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment.
Wysham C, Bajaj HS, Del Prato S, et al. · N Engl J Med 2024 · Clinical Trial, Phase III, Comparative Study
- Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy.
Rosenstock J, Bailey T, Connery L, et al. · N Engl J Med 2025 · Clinical Trial, Phase III, Equivalence Trial
- Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial.
Bergenstal RM, Weinstock RS, Mathieu C, et al. · Lancet 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial.
Blevins T, Dahl D, Pérez Manghi FC, et al. · Lancet 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial.
Philis-Tsimikas A, Bergenstal RM, Bailey TS, et al. · Lancet 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Once-Weekly Insulin Efsitora Alfa Versus Once Daily Insulin in Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Mehmood H, Alowami M, Hlaing TS, et al. · Endocrinol Diabetes Metab 2025 · Systematic Review, Meta-Analysis
Sponsor: Eli Lilly
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.